-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 19, Hongri Pharmaceuticals issued an announcement stating that the company had recently received a request from the US FDA regarding the consent for injection of Chrysene Chrysene B (CHS-201) (hereinafter referred to as "KB") for the treatment of sepsis.
In June 2014, KB was approved and issued by the National Medical Products Administration "Drug Clinical Trial Approval" (Lot No.
After obtaining the US FDA clinical trial qualification this time, KB's phase II clinical research plan for the treatment of patients with sepsis will be carried out in the United States
KB is a dual-target bacterial pathogen-related molecular antagonist, which treats sepsis by neutralizing bacterial endotoxin and bacterial genomic DNA, blocking or reducing the occurrence of inflammation